Cell technologies for muscle tissue restoration. Part II: skeletal and smooth muscles



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review represents ongoing clinical studies devoted to recovery of muscle tissue using cell technologies, as well as analysis of applied populations of cells.

Full Text

Restricted Access

About the authors

I. N Korsakov

A.I. Burnazyan Federal Medical Biophysical Center FMBA of Russia

V. L Zorin

A.I. Burnazyan Federal Medical Biophysical Center FMBA of Russia; Human Stem Cells Institute

I. I Eremin

A.I. Burnazyan Federal Medical Biophysical Center FMBA of Russia

A. I Zorina

Human Stem Cells Institute

K. V Kotenko

A.I. Burnazyan Federal Medical Biophysical Center FMBA of Russia

A. A Pulin

A.I. Burnazyan Federal Medical Biophysical Center FMBA of Russia

References

  1. Meregalli M., Farini A., Sitzia C. et al. Advancements in stem cells treatment of skeletal muscle wasting. Front Physiol. 2014; 5: 48.
  2. McCullagh К., Perlingeiro R. Coaxing stem cells for skeletal muscle repair. Adv. Drug Deliv. Rev. 2014; 1-10.
  3. Shi Х., Garry D.J. Muscle stem cells in development, regeneration, and disease. Genes Dev. 2006; 20: 1692-708.
  4. SampaolesiM., Blot S., D'Antona G. et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444: 574-9.
  5. Chang N., Rudnicki M. Satellite cells: the architects of skeletal muscle. Curr. Top. Dev. Biol. 2014; 107: 161-77.
  6. Rahimov F., KunkelL.M. The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J. Cell Biol. 2013; 201: 499-510.
  7. Kazuki Y., Hiratsuka M., Takiguchi M. et al. Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol. Ther. 2010; 18: 386-93.
  8. Ehmsen J., Poon E., Davies K. The dystrophin-associated protein complex. J.Cell Sci. 2002; 12: 2801-3.
  9. Durbeej M., Campbell K. Muscular dystrophies involving the dystrophinglycoprotein complex an overview of current models. Curr. Opin. Cenet. Dev. 2002; 12: 349-61.
  10. Sinha M., Jang J., Khong D. et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014; 344: 649-52.
  11. Emery A.E. The muscular dystrophies. Lancet 2002; 359: 687-95.
  12. Matsumura K., Ohlendieck K., Ionasescu V. et al. The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies. Neuromuscul.Disord. 1993; 3: 533-35.
  13. Farini A., Razini P., Erratico S. et al. Cell based therapy for duchenne muscular dystrophy. J. Cell. Physiol. 2009; 221: 526-34.
  14. Burdzinska A., Gala K., Pczek L. Myogenic stem cells. Folia Histochem. Cytobiol. 2008; 46(4): 401-12.
  15. Price F., Kuroda K., Rudnicki M. Stem cell based therapies to treat muscular dystrophy. Biochim.Biophys. 2007; 1772: 272-83.
  16. Gussoni E., Blau H., Kunkel L. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat. Med. 1997; 3: 970-6.
  17. Rinaldi F., Perlingeiro R.C. Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks. Transl. Res. 2014; 163(4): 409-17.
  18. Transplantation of myoblasts to duchenne muscular dystrophy (DMD) patients. http: //clinicaltrials.gov/show/ NCT02196467.
  19. Skuk D., Goulet M., Roy B. et al. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J.Neuropathol. Exp. Neurol. 2006; 65(4): 371-86.
  20. Study safety and efficacy of bone marrow derived autologous cells for the treatment of muscular dystrophy. http: //clinicaltrials.gov/ show/NCT01834066.
  21. Stem cell therapy in duchenne muscular dystrophy. http: // clinicaltrials.gov/show/NCT02241434.
  22. Study safety and efficacy of BMMNC for the patient with duchenne muscular dystrophy. http: //clinicaltrials.gov/show/ NCT01834040.
  23. Stem cell therapy in muscular dystrophy. http: //clinicaltrials. gov/show/NCT02241928.
  24. Cell therapy in limb girdle muscular dystrophy. http: // clinicaltrials.gov/ct2/show/NCT02245711?term=NCT02245711&ra nk=1.
  25. Stem cell therapy in limb girdle muscular dystrophy. http: // clinicaltrials.gov/ct2/show/NCT02050776?term=NCT02050776&ra nk=1.
  26. Intramuscular transplantation of muscle derived stem cell and adipose derived mesenchymal stem cells in patients with facioscapulohumeral dystrophy (FSHD). http: //clinicaltrials.gov/show/ NCT02208713.
  27. Tagliafico E., Brunelli S., Bergamaschi A. et al. TGFbeta/ BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. J. Cell Sci. 2004; 117: 4377-88.
  28. Minasi M.G., Riminucci M., De Angelis L. et al. The mesoangioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002; 129: 2773-83.
  29. De Angelis L., Berghella L., Coletta M. et al. Skeletal myogenic progenitors originating from embryonic dorsal aorta coexpress endothelial and myogenic markers and contribute to postnatal muscle growth and regeneration. J. Cell Biol. 1999; 147: 869-78.
  30. Suzuki M., McHugh J., Tork C. et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol.Ther. 2008; 16(12): 2002-10.
  31. Krakora D., Mulcrone P., Meyer M. et al. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol.Ther. 2013; 3: 1602-10.
  32. Dadon-Nachum M., Sadan O., Srugo I. et al. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Rev. 2011; 7: 664-71.
  33. Autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients with amyotrophic lateral sclerosis (ALS). http: //clinicaltrials.gov/show/ NCT01777646.
  34. Petrou P., Argov A., Lennon V.A.et al. Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy. Muscle Nerve 2014; 49: 455-7.
  35. Stem cell therapy to improve the muscle function of patients with partly denervatedmuscles of the arm. http: //clinicaltrials.gov/ show/NCT00755586.
  36. Safety and efficacy of IM injections of PLX-PAD for the regeneration of injured gluteal musculature after total hip arthroplasty. http: //clinicaltrials.gov/show/NCT01525667.
  37. Pluristem Therapeutics Inc. Pluristem'sphase I/II muscle injury trial successfully meets primary safety & efficacy endpoints, 2014. http: //www.pluristem.com/index.php/press-room/111-press-releases/press-room-2014/442-21-jan-2014.
  38. Treatment of dysphagia in oculopharyngealmuscular dystrophy by autologous transplantation of myoblasts (OPMD). http: // clinicaltrials.gov/show/NCT00773227.
  39. Perie S., Trollet C., Mouly V. et al. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study. Mol.Ther. 2014; 22: 219-25.
  40. Norton P., Brubaker L. Urinary incontinence in women. Lancet 2006; 367(9504): 57-67.
  41. Lin C.S., Lue T.F. Stem cell therapy for stress urinary incontinence: a critical review. Stem Cells Dev. 2012; 21(6): 834-43.
  42. Carr L.K., Steele D., Steele S. et al.1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int.Urogynecol. J. Pelvic. Floor Dysfunct. 2008; 19: 881-3.
  43. Sebe P., Doucet C., Cornu J.N. et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int. Urogynecol. J. 2011; 22: 183-9.
  44. Blaganje M., Lukanovic A. Ultrasound-guided autologous myoblast injections into the extrinsic urethral sphincter: tissue engineering for the treatment of stress urinary incontinence. Int. Urogynecol. J. 2013; 24(4): 533-5.
  45. Lee C.N., Jang J.B., Kim J.Y. et al. Human cord blood stem cell therapy for treatment of stress urinary incontinence. J. Korean. Med. Sci. 2010; 25: 813-6.
  46. Yamamoto T., Gotoh M., Kato M. et al. Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases. Int. J. Urol. 2012; 19(7): 652-9.
  47. Kuismanen K., Sartoneva R., Haimi S. et al. Autologous adipose stem cells in treatment of female stress urinary incontinence: results of a pilot study. Stem Cells Transl. Med. 2014; 3(8): 936-41.
  48. Transurethral myoblast injection for urinary incontinence in children with bladder exstrophy. http: //clinicaltrials.gov/show/ NCT02075216.
  49. Paraurethraltransplantation of autologous muscle derived stem cells for treatment of stress incontinency. http: //clinicaltrials. gov/show/NCT02156934.
  50. Muscle progenitor cell therapy for urinary incontinence.http: //clinicaltrials.gov/show/NCT01953315.
  51. Autologous muscle derived stem cells transplantation in urine incontinency.http: //clinicaltrials.gov/show/NCT01963455.
  52. Muscle derived cell therapy for bladder exstrophyepispadiasinduced incontinence (MDC).http: //clinicaltrials. gov/show/NCT01011777.
  53. Frudinger A., Kolle D., Schwaiger W. et al. Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up. Gut. 2010; 59 (1): 55-61.
  54. Romaniszyn M., Rozwadowska N., Nowak M. et al. Successful implantation of autologous muscle-derived stem cells in treatment of faecal incontinence due to external sphincter rupture. Int. J. Colorectal. Dis. 2013; 28(7): 1035-6.
  55. Autologous myoblast intrasphinctericinjection for fecal incontinence (MIAS).http: //clinicaltrials.gov/show/NCT01523522.
  56. Stem cells therapy for fecal incontinence in children after posterior sagittal ano-rectoplasty.http: //clinicaltrials.gov/show/ NCT02161003.
  57. Treatment of fecal Incontinence by injection of autologous muscle fibers into the anal sphincter.http: //clinicaltrials.gov/show/ NCT01949922.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies